FDA accepts Advancis' NDA for strep throat drug, shares jump

(Reuters) - Shares of the company were up $1.15 at $3.88 in morning trade on the Nasdaq.




Advancis said the FDA has set an action date of January 23, 2008 and if approved, expects to market the product at the beginning of 2008/2009 cough and cold season.


Read more at Reuters.com Hot Stocks News